FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953847488> ?p ?o ?g. }

• W2953847488 endingPage "277" @default.
• W2953847488 startingPage "261" @default.
• W2953847488 abstract "Artesunate the most potent antimalarial is widely used for the treatment of multidrug-resistant malaria. The antimalarial cytotoxicity of artesunate has been mainly attributed to its selective, irreversible and iron- radical-mediated damage of parasite biomolecules. In the present research, iron oxide nanoparticle fortified artesunate was tested in P. falciparum and in an experimental malaria mouse model for enhancement in the selectivity and toxicity of artesunate towards parasite. Artesunate was fortified with nontoxic biocompatible surface modified iron oxide nanoparticle which is specially designed and synthesized for the sustained pH-dependent release of Fe2+ within the parasitic food vacuole for enhanced ROS spurt.Antimalarial efficacy of Iron oxide nanoparticle fortified artesunate was evaluated in wild type and artemisinin-resistant Plasmodium falciparum (R539T) grown in O + ve human blood and in Plasmodium berghei ANKA infected swiss albino mice. Internalization of nanoparticles, the pH-dependent release of Fe2+, production of reactive oxygen species and parasite biomolecule damage by iron oxide nanoparticle fortified artesunate was studied using various biochemical, biophysical, ultra-structural and fluorescence microscopy. For determining the efficacy of ATA-IONP+ART on resistant parasite ring survival assay was performed.The nanoparticle fortified artesunate was highly efficient in the 1/8th concentration of artesunate IC50 and led to retarded growth of P. falciparum with significant damage to macromolecules mediated via enhanced ROS production. Similarly, preclinical In vivo studies also signified a radical reduction in parasitemia with ~8-10-fold reduced dosage of artesunate when fortified with iron oxide nanoparticles. Importantly, the ATA-IONP combination was efficacious against artemisinin-resistant parasites.Surface coated iron-oxide nanoparticle fortified artesunate can be developed into a potent therapeutic agent towards multidrug-resistant and artemisinin-resistant malaria in humans. FUND: This study is supported by the Centre for Study of Complex Malaria in India funded by the National Institute of Health, USA." @default.
• W2953847488 created "2019-07-12" @default.
• W2953847488 creator A5005104563 @default.
• W2953847488 creator A5036815258 @default.
• W2953847488 creator A5038040205 @default.
• W2953847488 creator A5051500824 @default.
• W2953847488 creator A5057590652 @default.
• W2953847488 creator A5069082684 @default.
• W2953847488 creator A5081408064 @default.
• W2953847488 date "2019-07-01" @default.
• W2953847488 modified "2023-10-14" @default.
• W2953847488 title "Pre-clinical study of iron oxide nanoparticles fortified artesunate for efficient targeting of malarial parasite" @default.
• W2953847488 cites W1528480178 @default.
• W2953847488 cites W1567614586 @default.
• W2953847488 cites W1961019246 @default.
• W2953847488 cites W1969503178 @default.
• W2953847488 cites W1973150223 @default.
• W2953847488 cites W1974023961 @default.
• W2953847488 cites W1991701295 @default.
• W2953847488 cites W1993347313 @default.
• W2953847488 cites W1993566791 @default.
• W2953847488 cites W1996418116 @default.
• W2953847488 cites W1998835931 @default.
• W2953847488 cites W2000312340 @default.
• W2953847488 cites W2001229704 @default.
• W2953847488 cites W2002222120 @default.
• W2953847488 cites W2014387796 @default.
• W2953847488 cites W2015823022 @default.
• W2953847488 cites W2023633070 @default.
• W2953847488 cites W2035303586 @default.
• W2953847488 cites W2035826427 @default.
• W2953847488 cites W2044811771 @default.
• W2953847488 cites W2048400708 @default.
• W2953847488 cites W2055042140 @default.
• W2953847488 cites W2058821103 @default.
• W2953847488 cites W2061668975 @default.
• W2953847488 cites W2062553485 @default.
• W2953847488 cites W2072993752 @default.
• W2953847488 cites W2076029682 @default.
• W2953847488 cites W2081703573 @default.
• W2953847488 cites W2082769422 @default.
• W2953847488 cites W2089288068 @default.
• W2953847488 cites W2089710981 @default.
• W2953847488 cites W2094870284 @default.
• W2953847488 cites W2096787650 @default.
• W2953847488 cites W2102216674 @default.
• W2953847488 cites W2111813303 @default.
• W2953847488 cites W2117080863 @default.
• W2953847488 cites W2118637056 @default.
• W2953847488 cites W2121762116 @default.
• W2953847488 cites W2126649249 @default.
• W2953847488 cites W2127975274 @default.
• W2953847488 cites W2129428401 @default.
• W2953847488 cites W2135926190 @default.
• W2953847488 cites W2139017151 @default.
• W2953847488 cites W2155866715 @default.
• W2953847488 cites W2159865605 @default.
• W2953847488 cites W2161311583 @default.
• W2953847488 cites W2169242620 @default.
• W2953847488 cites W2181657564 @default.
• W2953847488 cites W2184709802 @default.
• W2953847488 cites W2234562695 @default.
• W2953847488 cites W2340662778 @default.
• W2953847488 cites W2341201725 @default.
• W2953847488 cites W2427645657 @default.
• W2953847488 cites W2530691642 @default.
• W2953847488 cites W2778503014 @default.
• W2953847488 cites W2783508801 @default.
• W2953847488 cites W4211136995 @default.
• W2953847488 cites W54424315 @default.
• W2953847488 cites W91444433 @default.
• W2953847488 doi "https://doi.org/10.1016/j.ebiom.2019.06.026" @default.
• W2953847488 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6642363" @default.
• W2953847488 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31255656" @default.
• W2953847488 hasPublicationYear "2019" @default.
• W2953847488 type Work @default.
• W2953847488 sameAs 2953847488 @default.
• W2953847488 citedByCount "34" @default.
• W2953847488 countsByYear W29538474882020 @default.
• W2953847488 countsByYear W29538474882021 @default.
• W2953847488 countsByYear W29538474882022 @default.
• W2953847488 countsByYear W29538474882023 @default.
• W2953847488 crossrefType "journal-article" @default.
• W2953847488 hasAuthorship W2953847488A5005104563 @default.
• W2953847488 hasAuthorship W2953847488A5036815258 @default.
• W2953847488 hasAuthorship W2953847488A5038040205 @default.
• W2953847488 hasAuthorship W2953847488A5051500824 @default.
• W2953847488 hasAuthorship W2953847488A5057590652 @default.
• W2953847488 hasAuthorship W2953847488A5069082684 @default.
• W2953847488 hasAuthorship W2953847488A5081408064 @default.
• W2953847488 hasBestOaLocation W29538474881 @default.
• W2953847488 hasConcept C185592680 @default.
• W2953847488 hasConcept C203014093 @default.
• W2953847488 hasConcept C2775867548 @default.
• W2953847488 hasConcept C2776120307 @default.
• W2953847488 hasConcept C2777237215 @default.
• W2953847488 hasConcept C2778048844 @default.
• W2953847488 hasConcept C2778059366 @default.

• next